HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Infectious Disease13 papers

Viral hepatitis C

Last edited: 4/10/2026

Overview

Hepatitis C virus (HCV) infection is a significant global public health concern. While no prophylactic vaccine is currently available, vaccination strategies are being explored 3. Understanding the prevalence of HCV in various populations is crucial for elimination efforts 2.

Diagnosis

Management

  • No specific management strategies for HCV are detailed in the provided abstracts. Abstract 1 discusses treatment for chronic hepatitis B virus (HBV) infection with tenofovir alafenamide (TAF).

    • Special Populations

    Key Recommendations

  • Detailed knowledge of HCV prevalence in diverse populations is required to evaluate the impact of efforts to support WHO HCV elimination goals 2. (Evidence: Moderate)
  • DNA-based immunization is a promising modality to generate cellular and humoral immune responses against HCV, and various strategies exist to optimize their efficacy 3. (Evidence: Moderate)
  • Further research into HCV DNA vaccines is needed, as no prophylactic vaccine is currently available 3. (Evidence: Moderate)

    • References

    1 Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR et al.. Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. Alimentary pharmacology & therapeutics 2024. link 2 Iversen J, Wand H, Chan PL, Le LV, Maher L. Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region. Viruses 2022. link 3 Shayeghpour A, Kianfar R, Hosseini P, Ajorloo M, Aghajanian S, Hedayat Yaghoobi M et al.. Hepatitis C virus DNA vaccines: a systematic review. Virology journal 2021. link

    Original source

    1. [1]
      Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. — Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR et al. Alimentary pharmacology & therapeutics (2024)
    2. [2]
      Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region. — Iversen J, Wand H, Chan PL, Le LV, Maher L Viruses (2022)
    3. [3]
      Hepatitis C virus DNA vaccines: a systematic review. — Shayeghpour A, Kianfar R, Hosseini P, Ajorloo M, Aghajanian S, Hedayat Yaghoobi M et al. Virology journal (2021)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG